Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloStim (StimVax) in third-line metastatic colorectal cancer
NCT04444622Phase 2Completed
- Sponsor
- Mirror Biologics, Inc.
- Start
- Jul 2021
- Primary completion
- Mar 2025
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of allostim in metastatic colorectal cancer (mCRC), sponsored by Mirror Biologics, Inc.. Started Jul 2021; status: completed.
02
Drugs
allostim
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04444622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04444622.